Skip Navigation



NDT Advance Access published online on August 23, 2009

Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfp421
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Yu, F.
Right arrow Articles by Zhao, M.-H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yu, F.
Right arrow Articles by Zhao, M.-H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org



Lupus nephritis combined with renal injury due to thrombotic thrombocytopaenic purpura-haemolytic uraemic syndrome

Feng Yu*, Ying Tan* and Ming-Hui Zhao

Renal Division, Department of Medicine, Peking University First Hospital, Institute of Nephrology, Peking University, and Key Laboratory of Renal Disease, Ministry of Health of China, Beijing 100034, People's Republic of China

Correspondence and offprint requests to: Ming-Hui Zhao; E-mail:mhzhao{at}bjmu.edu.cn



  Abstract

Background. Thrombotic thrombocytopaenic purpura–haemolytic uraemic syndrome (TTP–HUS) in SLE was reported mainly in isolated case reports. The aim of this study is to investigate the clinical and pathological features, outcome and possible pathogenesis of TTP–HUS in patients with lupus nephritis.

Methods. Clinical and renal histopathological data of patients with lupus nephritis were reviewed for clinical and pathological evidence of both TTP–HUS and renal thrombotic microangiopathy (TMA). Serum ADAMTS-13 activity and ADAMTS-13 autoantibodies were further studied.

Results. Seven patients with evidence of both TTP–HUS and renal TMA were identified in 353 patients with lupus nephritis. In comparison with 55 patients with lupus nephritis without TTP–HUS, those with TTP–HUS had a higher prevalence of acute renal failure and worse renal outcome. The serum ADAMTS-13 activity was significantly lower in patients with both lupus nephritis and TTP–HUS than in patients with lupus nephritis only and in normal control (40% versus 69%, P = 0.012; 40% versus 81%, P < 0.001, respectively). The prevalence of ADAMTS-13 autoantibodies was significantly higher in patients with both lupus nephritis and TTP–HUS than in patients with lupus nephritis only and in normal control (6/7, 86% versus 10/55, 18%, P < 0.001; 6/7, 86% versus 0, P < 0.001, respectively). After clinical remission, the serum ADAMTS-13 activity of the seven patients with TTP–HUS increased significantly (40% versus 63%, P < 0.001) and five out of the six patients with positive ADAMTS-13 autoantibodies turned negative.

Conclusions. ADAMTS-13 autoantibodies might play an important role in the pathogenesis of TTP–HUS associated with lupus nephritis. The long-term outcome seems to be worse in patients with both TTP–HUS and lupus nephritis than in patients with lupus nephritis alone.

Keywords: ADAMTS-13; haemolytic uraemic syndrome; lupus nephritis; thrombotic thrombocytopaenic purpura; von Wilebrand factor


* Both authors contributed equally to this work.

Received for publication: 2. 1.09
Accepted in revised form: 27. 7.09


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.